There are currently 439 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - 017-820F, Kansas City, Missouri +1 locations
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Kansas City VA Medical Center, Kansas City, Missouri
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
HER2-positive Breast Cancer Registry
NCT06603597
Recruiting
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: KUCC - North, Kansas City, Missouri
Conditions: HER2 + Breast Cancer
Register for Updates
Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer
NCT05958316
Recruiting
Determine the effects of the Computerized Symptom Assessment Tool (C-SCAT) versus usual care on the primary outcomes of self-efficacy for symptom management and symptom self-management behaviors
Gender:
ALL
Ages:
Between 15 years and 29 years
Trial Updated:
09/26/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Symptoms and Signs, Cancer, Childhood Cancer
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: Children's Mercy, Kansas City, Missouri
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: Neuroblastoma
Register for Updates
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Register for Updates
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
NCT05446272
Recruiting
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
Gender:
ALL
Ages:
Between 0 days and 9 weeks
Trial Updated:
09/09/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
Register for Updates
Compassionate Use of Domperidone for Refractory Gastroparesis
NCT04699591
Recruiting
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
09/05/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: GERD, Gastroesophageal Reflux, Gastroparesis
Register for Updates
Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
NCT05889156
Recruiting
This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment. The two periods consist of: 1. A 3-week screening period that includes a TG qualifying period, and 2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment p... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
09/04/2024
Locations: Clay Platte Family Medicine / CCT Research, Kansas City, Missouri
Conditions: High Triglycerides
Register for Updates
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
NCT05727878
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Principal Investigator, Kansas City, Missouri +1 locations
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
The PROTEMBO Trial
NCT05873816
Recruiting
The goal of this prospective, multi-center, randomized, controlled study is to compare the safety and efficacy of the ProtEmbo Cerebral Embolic Protection device to a hybrid control (no embolic protection device ('No Device') and the Sentinel device) in subjects with severe symptomatic native aortic valve stenosis indicated undergoing a TAVR procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Severe Aortic Valve Stenosis
Register for Updates